Shanghai Aidefa Pharmacy Co. Ltd.

This study aimed to investigate the pharmacokinetic characteristics of mesalazine sustained-release granules (1 g) developed and produced by Shanghai Aifa Pharmaceutical Co., Ltd., after a single fasting and postprandial oral administration. Mesalazine sustained-release granules (Pentasa®, 1 g) produced by Ferring GmbH were used as a reference formulation. The pharmacokinetic parameters Cmax and AUC of the test formulation and the reference formulation were compared to evaluate the bioequivalence of the two formulations in humans.

This study aimed to investigate the pharmacokinetic characteristics of fenofibrate capsules (0.2 g) developed and produced by Shanghai Aifa Pharmaceutical Co., Ltd. after single oral administration on an empty stomach or after a meal; using fenofibrate capsules (Lipingzhi®, 200 mg) certified by Abbott Laboratories Limited as the reference preparation, the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared, and the bioequivalence of the two preparations in humans was evaluated.

The bioequivalence of a single oral dose of 20 mg of clobazam oral suspension provided by Shanghai Aifa Pharmaceutical Co., Ltd. (test preparation, trade name: Tapclob®, strength: 10 mg/5 mL) or a single oral dose of 20 mg of clobazam oral suspension certified by Lundbeck Pharmaceuticals LLC (reference preparation, trade name: Onfi®, strength: 2.5 mg/mL) was investigated under fasting and postprandial conditions.